Firm fixed price award center for drug evaluation (cder) and research office of new drugs - office of therapeutic biologics and biosimilars (otbb) biosimilar user fee act i program - biosimilar and…
Ended Awarded Last action
- Contract number
- 75F40122F19006
- Awardee
-
Booz Allen Hamilton Inc. UEI JCBMLGPE6Z71 Part of Booz Allen Hamilton Holding Corporation
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $1,099,980
Award facts
- Contract value 100% obligated
- $1,099,979.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Silver Spring, MD 20993, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $500,000 | |
| Other Administrative Action | $0 | |
| Original award | $599,980 |
About this award
This is a firm fixed-price award from the Food and Drug Administration (FDA) to Booz Allen Hamilton Inc. for the Center for Drug Evaluation and Research (CDER) Office of Therapeutic Biologics and Biosimilars (OTBB) Biosimilar User Fee Act I Program. The $1,099,979.78 contract is for biosimilar and interchangeable product education, uptake, and implementation services. The award does not have a set-aside designation. Booz Allen Hamilton Inc. is a leading provider of management, technology, and engineering services to the U.S. government, specializing in defense, intelligence, and civil markets. The company has an extensive history of providing a wide range of services through prime and subcontract awards across various federal agencies.
Description
Firm fixed price award center for drug evaluation (cder) and research office of new drugs - office of therapeutic biologics and biosimilars (otbb) biosimilar user fee act i program - biosimilar and interchangeable product education, uptake, and IMP
Quick answers
Who was awarded contract 75F40122F19006?
75F40122F19006 was awarded to Booz Allen Hamilton Inc. by Food and Drug Administration (Department of Health and Human Services) on August 10, 2022.
How much is contract 75F40122F19006 worth?
The government has obligated $1,099,980 on 75F40122F19006.
Is contract 75F40122F19006 an order under another contract?
Yes. 75F40122F19006 is a BPA call under GS00F008DA-75F40122A00008, a blanket purchase agreement, on Multiple Award Schedule (MAS).
Was contract 75F40122F19006 competed?
The extent of competition for 75F40122F19006 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award